Blocking a 'jamming signal' can unleash immune system to fight tumors

June 24, 2020

Yale researchers have discovered a "jamming signal" that blocks a powerful immune system stimulant called interleukin-18 (IL-18) from reaching tumors, including in cancers that are resistant to conventional immunotherapy treatments, they report June 24 in the journal Nature.

The research team created a version of IL-18 that could not be jammed and significantly reduced tumors in mice that are resistant to current immunotherapy.

Interleukin-18 is part of a vast immune system arsenal called cytokines and has the specific role of mobilizing T cells and "natural killer" cells to combat infections. Because of this activity, pharmaceutical companies had previously tried to use IL-18 as a cancer treatment. However, the approach failed to show any benefit in clinical trials.

"This was a major paradox to us because IL-18 sends an incredibly powerful inflammatory message to the 'right' immune cells that attack tumors," said Yale's Aaron Ring, assistant professor of immunobiology and pharmacology and senior author of the research. "The fact that there was no response to natural IL-18 in previous clinical trials made us think that tumors were employing immunological countermeasures"

The Yale team set out to find out how tumors shut down IL-18. They discovered that within many forms of cancer, there are high levels of a protein called interleukin-18 binding protein (IL-18BP), which acts as "decoy receptor," blocking the ability of IL-18 to bind to its receptor on immune system cells and activate an immune response.

"We figured that IL-18 was the right pathway to engage, but that IL-18BP was acting as a barrier to its activity," Ring said. "So we wondered if we could make a synthetic version of IL-18 that could overcome this problem."

Using a process called directed evolution, Ring's team searched through approximately 300 million different mutant forms of IL-18 to find rare variants that only bound the true IL-18 receptor and not the decoy.

"We just changed IL-18's frequency in order to eliminate the jamming signal," Ring said.

Working with the laboratory of co-author Marcus Bosenberg, interim director of the Yale Center for Immuno-oncology and professor of dermatology, pathology, and immunobiology, the team administered the modified IL-18 to mice with a variety of tumor types, including those resistant to conventional immunotherapy. They found that the synthetic IL-18 greatly reduced the growth of the tumors and was able to completely eradicate cancer in many of the mice. When they looked within the tumors, the team discovered that the IL-18 drug worked to increase the numbers of an important population of "stem-like" T cells that sustain effective anti-tumor responses.

Existing cancer immunotherapies have proved highly successful in attacking so-called "hot tumors" or those characterized by the presence of inflammation. However, "cold" tumors or those lacking immune system activity, have been resistant to forms of immunotherapy currently in use.

"Because IL-18 can act on cells of the 'innate' immune system such as natural killer cells, it has potential to be effective against 'cold tumors' that have become resistant to conventional immunotherapies," said Bosenberg. "This is a major unmet need and one that the IL-18 pathway is poised to address."

Ring has formed a company called Simcha Therapeutics and hopes to begin clinical trials of the drug in cancer patients next year.
-end-
Yale's Ting Zhou, postdoctoral research associate, William Damsky, instructor of dermatology, and Orr-El Weizman, immunobiology graduate student, are co-first authors of the paper.

Primary funding for the research was provided by the National Cancer Institute's Immuno-Oncology Translational Network, Gabrielle's Angel Foundation, the Pew Charitable Trusts and the Blavatnik Fund for Innovation at Yale

Yale University

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.